The Foundation for Women’s Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to End Women’s Cancer
October 18, 2017 08:00 ET
|
TESARO, Inc.
CHICAGO and WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology, and TESARO, Inc. (NASDAQ:TSRO),...
TESARO Receives Positive CHMP Opinion for ZEJULA®
September 15, 2017 07:45 ET
|
TESARO, Inc.
ZUG, Switzerland, Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee...
TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
August 25, 2017 08:01 ET
|
TESARO, Inc.
WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data from nine abstracts will be presented at the...
TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017
July 25, 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2017 financial results on Tuesday, August 8, 2017, after the close of the U.S. financial...
TESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference
June 07, 2017 16:30 ET
|
TESARO, Inc.
WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global...
TESARO Provides Business and Pipeline Update at ASCO Investor Briefing
June 03, 2017 18:30 ET
|
TESARO, Inc.
Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancerPhase 1 results for TSR-042 show anti-PD-1...
Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2017 16:15 ET
|
TESARO, Inc.
Investor briefing to be webcast from Chicago on June 3, 2017 at 6:15 PM CT WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical...
National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community
May 22, 2017 09:01 ET
|
TESARO, Inc.
WALTHAM, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the results of the Our Way Forward survey – a national...
TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer
May 11, 2017 02:01 ET
|
TESARO, Inc.
WALTHAM, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- TESARO Inc. (NASDAQ:TSRO) and Clinigen Group plc’s (AIM:CLIN) ('Clinigen') Idis Managed Access division have partnered to launch a Managed Access...
TESARO Announces First-Quarter 2017 Operating Results
May 09, 2017 16:05 ET
|
TESARO, Inc.
ZEJULA™ approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical...